Tag:

R&D

Latest Headlines

Latest Headlines

Lilly heads to Cambridge, MA, as Big Pharma gentrifies a biotech hotbed

Eli Lilly is the latest multinational drugmaker looking to Cambridge, MA, to jump-start its innovation engine, blueprinting a new R&D outpost on the Charles River as biotech's hippest neighborhood gets more and more crowded.

City of Hope, Fortress Biotech form new company to ward off CMV

Cytomegalovirus (CMV) presents no symptoms in most healthy people, but it can be life-threatening in people with weakened or underdeveloped immune systems. So City of Hope and Fortress Biotech have joined the race to produce vaccines to control CMV infections.

Tobira pulls off a $40M Wall Street end-around with sights set on NASH

After striking out in a solo IPO attempt, Tobira Therapeutics has executed a reverse merger with the stalled Regado Biosciences, raising $40 million to target a pervasive liver disease.

GlaxoSmithKline files for gene therapy OK as a case of the jitters sets in

Close to 5 years after GlaxoSmithKline signed on to collaborate with the San Raffaele Telethon Institute for Gene Therapy in Italy, the partners have stepped up with a European application to start marketing a gene therapy for extraordinarily rare cases of immune deficiency triggered by ADA-SCID. And its delivery into regulatory hands comes as the gene therapy field has been recoiling from some notable setbacks that have begun to cloud what has been a bullish sector in biotech.

Big new launches rocket cancer drug spending to $100B: IMS report

Cancer drug pricing is turning more and more heads, especially as critical payers threaten a crackdown in the oncology field. And there's a reason for all the hullaballoo: Spending on oncology meds is increasing rapidly, new IMS numbers show.

Scientists harness new technology for artificial knee implants

As the med tech industry targets innovative technologies to treat orthopedic injuries, scientists are developing artificial knee implants that could help ward off arthritis and surgery further down the road.

NIH funds 5 projects to treat blindness, unveils Alzheimer's research agenda

The U.S. National Institutes of Health's National Eye Institute is spending up to $17.9 million over the next 5 years to find new therapies for blindness. In addition, the NIH just unveiled its Alzheimer's disease research agenda.

Boston Scientific: Watchman and Lotus TAVR will power future growth, boost margins

At its investor day on May 1, Boston Scientific pledged to accelerate sales growth to 3% to 6% and boost its operating margins to 25% by 2017 on the back of a promising product pipeline, like the newly approved Watchman device for preventing stroke and the next generation of its fast selling S-ICD, which reduces implantable defibrillators' reliance on troublesome wires known as leads.

Waksal's new biotech spins out its gene therapy biz with an IPO in mind

Kadmon, a biotech company founded by the once-jailed former CEO of ImClone, is spinning out its gene therapy division on the path to a long-promised IPO, touting a novel approach to the fast-moving field.

Missouri scientists seek public's help in quest to sequence feline genomes

The feline genetics laboratory at the University of Missouri's veterinary college has set an ambitious goal to sequence the genomes of 99 cats. Leslie Lyons, professor emeritus and principal investigator, hopes the genetic information gathered during the project will help veterinarians, breeders, and cat owners eliminate some genetic diseases.